guest ::
| Home > Publications database > Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia. > print |
| Home > Publications database > Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia. > print |
| 001 | 125471 | ||
| 005 | 20240228143309.0 | ||
| 024 | 7 | _ | |a 10.1038/leu.2015.317 |2 doi |
| 024 | 7 | _ | |a pmid:26582645 |2 pmid |
| 024 | 7 | _ | |a 0887-6924 |2 ISSN |
| 024 | 7 | _ | |a 1476-5551 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2017-01597 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Balss, J. |0 P:(DE-HGF)0 |b 0 |e First author |
| 245 | _ | _ | |a Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia. |
| 260 | _ | _ | |a Basingstoke |c 2016 |b Nature Publ. Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1524211749_23437 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Mutations in isocitrate dehydrogenases (IDHs) 1 and 2 frequently occur in acute myeloid leukemia (AML) and result in the production of the oncometabolite d-2-hydroxyglutarate (D2HG). D2HG has been shown to promote leukemogenesis even in the absence of mutated IDH, but the prognostic significance of pretreatment serum D2HG levels in patients with IDH-mutated AML is unclear. We measured D2HG serum levels in 84 patients with IDH-mutated AML treated in the prospective, randomized multicenter AML2003 trial of the German Study Alliance Leukemia. Multivariate Cox regression showed D2HG levels to negatively impact on event-free survival (EFS) as a continuous variable in the entire IDH(mut) cohort (P=0.04), with no effect on overall survival (OS). In a subgroup analysis, the negative impact of D2HG on EFS was found to be restricted to patients with mutations in IDH1 (P=0.003), adjusted for age, leukocyte count, serum lactate dehydrogenase and European LeukemiaNet risk score. We thus conclude that pretreatment D2HG serum levels may yield prognostic information in patients with IDH1-mutated, but not in IDH2-mutated AML, possibly due to different subcellular localizations of IDH1 and IDH2. |
| 536 | _ | _ | |a 317 - Translational cancer research (POF3-317) |0 G:(DE-HGF)POF3-317 |c POF3-317 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Biomarkers, Tumor |2 NLM Chemicals |
| 650 | _ | 7 | |a Glutarates |2 NLM Chemicals |
| 650 | _ | 7 | |a alpha-hydroxyglutarate |0 2889-31-8 |2 NLM Chemicals |
| 650 | _ | 7 | |a Isocitrate Dehydrogenase |0 EC 1.1.1.41 |2 NLM Chemicals |
| 650 | _ | 7 | |a IDH1 protein, human |0 EC 1.1.1.42. |2 NLM Chemicals |
| 700 | 1 | _ | |a Thiede, C. |b 1 |
| 700 | 1 | _ | |a Bochtler, T. |0 P:(DE-He78)c741dc7f974390ad4310349f29aac40b |b 2 |u dkfz |
| 700 | 1 | _ | |a Okun, J. G. |b 3 |
| 700 | 1 | _ | |a Saadati, M. |0 P:(DE-He78)609d3f1c1420bf59b2332eeab889cb74 |b 4 |u dkfz |
| 700 | 1 | _ | |a Benner, A. |0 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |b 5 |u dkfz |
| 700 | 1 | _ | |a Pusch, Stefan |0 P:(DE-He78)f2efee17b6ca2f790176a2c036912536 |b 6 |u dkfz |
| 700 | 1 | _ | |a Ehninger, G. |b 7 |
| 700 | 1 | _ | |a Schaich, M. |b 8 |
| 700 | 1 | _ | |a Ho, A. D. |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a von Deimling, A. |0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144 |b 10 |u dkfz |
| 700 | 1 | _ | |a Krämer, A. |0 P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0 |b 11 |u dkfz |
| 700 | 1 | _ | |a Heilig, Christoph |0 P:(DE-He78)42b6114cd48e033299b2b6ef4bf56cc6 |b 12 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1038/leu.2015.317 |g Vol. 30, no. 4, p. 782 - 788 |0 PERI:(DE-600)2008023-2 |n 4 |p 782 - 788 |t Leukemia |v 30 |y 2016 |x 1476-5551 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:125471 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)c741dc7f974390ad4310349f29aac40b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)609d3f1c1420bf59b2332eeab889cb74 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)f2efee17b6ca2f790176a2c036912536 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)42b6114cd48e033299b2b6ef4bf56cc6 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-317 |2 G:(DE-HGF)POF3-300 |v Translational cancer research |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b LEUKEMIA : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b LEUKEMIA : 2015 |
| 920 | 1 | _ | |0 I:(DE-He78)G380-20160331 |k G380 |l KKE Neuropathologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)G330-20160331 |k G330 |l KKE Molekulare Hämatologie/Onkologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)L101-20160331 |k L101 |l DKTK Heidelberg |x 3 |
| 920 | 1 | _ | |0 I:(DE-He78)L301-20160331 |k L301 |l DKTK Dresden |x 4 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)G380-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G330-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L101-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L301-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|